Replies to post #33 on Editas Medicine Inc (EDIT)

[Justfactsmam]

"Upgrade this AM by Chardan...Price Target: $65.00 (triple current SP). $65.00 based upon 3 different valuation methods with $65.00 being the "average"...meaning of course one or two were ABOVE $65.00."

Chardan notes: ... bullish on CRISPPR technology "vast potential" ...Editas has the greater upside potential vs other U.S. companies